AstraZeneca reveals plans to use $500m to establish a global R&D centre and its corporate headquarters in Cambridge.

Global pharmaceutical firms AstraZeneca is to invest $500m in the construction of a new global R&D centre and the relocation of its headquarters in Cambridge.

The announcement comes as part of a wider company plan to establish three R&D centres in the UK, the US and Sweden to drive biopharmaceutical research.

The company, which will be bringing 2,000 new jobs to the area, said that it was attracted to the Cambridge tech cluster by the easy access to scientific talent…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?